Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 254 results for "mirati"

Mirati Therapeutics To Present Abstracts On Pipeline Programs At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting

Mirati Therapeutics To Present Abstracts On Pipeline Programs ...

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that abstracts on its investigational tyrosine kinase inhibitor candidates, glesatinib (MGCD265) and sitravatinib (MGCD516), will be presented at the 2016 American Society of ... Barchart, 1 week ago
Mirati Therapeutics reports Q1 EPS ($1.13), consensus (99c) Pettinga Financial Advisors, 3 weeks ago

2 images for "mirati"

ADVFN India, 1 week ago
Oregon Public Broadcasting, 3 weeks ago

MIRATI THERAPEUTICS, INC. FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. Our 2016 Annual Meeting of Stockholders was held on May 18, 2016. We had 19,538,796 shares of common stock outstanding and entitled to vote as of March 24, 2016, the record date for
 Equities.com3 days ago CT ORDER - Mirati Therapeutics, Inc. (0001576263) (Filer)  SEC1 week ago 10-Q - Mirati Therapeutics, Inc. (0001576263) (Filer)  SEC Filings3 weeks ago Mirati Therapeutics, Inc. Files SEC Form DEF 14A, Other Definitive Proxy Statements (Apr. 19, 2016)  Equities.com4 weeks ago

Mirati Therapeutics misses by $0.14

News Editor Mirati Therapeutics (NASDAQ:MRTX): Q1 EPS of -$1.13 misses by $0.14. Comments (0) Be the first to comment All (0) Author's Picks () Load All Comments DJIA (DIA) S&P 500 (SPY) ETF Hub ETF Screener: Search and filter by ...
 Seeking Alpha3 weeks ago

BRIEF-Mirati therapeutics- appoints Jamie A. Donadio as CFO

March 23 (Reuters) - * Mirati Therapeutics inc says prior to joining Mirati, donadio was with Amylin pharmaceuticals inc, most recently serving as senior director of finance * Mirati Therapeutics announces promotion of Jamie A. Donadio to ...
 Reuters UK2 months ago

QIAGEN NV : partnersetoodevelop novel compancodediagnosticein lungocanc r var

Collaboration with Mirati Therapeutics targets MET gene mutations to
 4 Traders1 month ago QIAGEN Partners with Mirati Therapeutics, Inc.  Advance for Respiratory Care & Sleep Medicine1 month ago QIAGEN Partners to Develop Novel Companion Diagnostic in Lung Cancer  Sys-Con Canada1 month ago BRIEF-Qiagen Partners to develop novel companion diagnostic in lung cancer  Reuters UK1 month ago

Analysts Recent Ratings Changes for Mirati Therapeutics (MRTX)

Mirati Therapeutics (NASDAQ: MRTX) has recently received a number of price target changes and ratings updates: 5/24/2016 Mirati Therapeutics had its outperform rating reaffirmed by analysts at Wedbush. They now have a $29.00 price target on the ...
 Ticker Report4 hours ago
American Banking News - Earnings

Wedbush Reaffirms $29.00 Target On Mirati Therapeutics (NASDAQ:MRTX), Reaffirms Outperform Rating

Mirati Therapeutics (NASDAQ:MRTX) Rating Restated Wedbush currently has a $29.00 price target on the $335.63M market cap company or 72.00 % upside potential. In a note released on 24 May, Mirati Therapeutics (NASDAQ:MRTX) stock had its Outperform ...
 Octafinance2 days ago Mirati Therapeutics, Inc. (MRTX) Given New $29.00 Price Target at Wedbush  American Banking News2 days ago Mirati Therapeutics, Inc. (MRTX) to Post FY2018 Earnings of ($5.58) Per Share, Wedbush Forecasts  American Banking News6 hours ago Mirati Therapeutics, Inc. (MRTX) Stock Rating Reaffirmed by Wedbush  SleekMoney16 hours ago

TIAA CREF Investment Management LLC Has $757,000 Stake in Mirati Therapeutics, Inc. (MRTX)

TIAA CREF Investment Management LLC continued to hold its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) during the first quarter, Holdings Channel reports. The fund owned 35,395 shares of the company's stock at the end of the first ...
 WKRB News19 hours ago Rhenman & Partners Asset Management AB Continues to Hold Stake in Mirati Therapeutics, Inc. (MRTX)  Ticker Report2 days ago

Which Of The Latest 13F Filers Holds Mirati Therapeutics?

| CEOWORLD Financial | Chief Executive Forum Register Now Lost Password Lost your password? Please enter your email address. You will receive a link and will create a new password via email. May 17, 2016 at 09:27 AM EDT ...
 CEOWorld Magazine1 week ago

Mirati Therapeutics (MRTX) Analysts Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Mirati Therapeutics (NASDAQ: MRTX) recently: 5/12/2016 Mirati Therapeutics is now covered by analysts at Piper Jaffray. They set a hold rating and a $17.00 price target on ...
 Ticker Report1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less